FDA grants breakthrough status to prostate cancer drug


Novartis' tumor-targeting radiation therapy for castration-resistant prostate cancer, Lu-PSMA-617, was granted breakthrough therapy designation by the FDA. The treatment attaches lutetium-177, a radioactive isotope, to PSMA-617, a small molecule drug, to eliminate cancer cells while limiting potential damage to healthy cells surrounding it.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.